EGFR and non-small cell lung carcinoma: The results indicated that the combination treatments enhanced the suppressive effect on both EGFR bypass pathways and downstream tyrosine kinases that play key roles in the pro-oncogenic signaling of NSCLC, thereby potentiating the inhibitory effects of EGFR-TKIs on innate resistant NSCLC cells.